Introduction
============

In the US, prostate cancer is the most commonly diagnosed malignancy and the second leading cause of mortality from cancer in men.[@b1-cmr-3-109] In 1997, there were at least 209,900 new cases of prostate cancer diagnosed and more than 41,800 deaths from prostate cancer.[@b2-cmr-3-109] At present, a transrectal ultrasound with prostatic biopsy is recommended in men with an abnormal digital rectal examination and/or an elevated prostate-specific antigen (PSA) level, and who are potential candidates for therapy.

According to the US Bureau of the Census in 1998, there were an estimated 30 million men in the US over the age of 50 years.[@b3-cmr-3-109] A subset of this population represents those men who should undergo screening according to recommendations made by the American Urological Association.[@b4-cmr-3-109] In a study by Arcangeli et al,[@b6-cmr-3-109] 8%--15% of men screened were estimated to have an abnormal PSA test (ie, serum PSA ≥ 4.1 ng/mL by monoclonal assay) or had an abnormal digital rectal examination, half of whom had no identifiable pathology on biopsy.[@b5-cmr-3-109] A further study has shown that about 66% of men with abnormally elevated PSA levels go on to have a negative biopsy,[@b6-cmr-3-109] and another showed that 19%--32% of men who agreed to undergo biopsy were found to have prostate cancer.[@b5-cmr-3-109] An indicator/marker adjunctive to the digital rectal examination and PSA would help the clinician in the decision to perform a biopsy.

Bioimpedance is an electrical property of living tissue that has been shown to be a safe technique when used in a number of biomedical applications, including for quantification of brain edema in neurosurgery[@b7-cmr-3-109] and for differentiating between cancer and pneumonia on discovery of a pulmonary mass.[@b8-cmr-3-109] Electric current is normally limited in living tissue by highly insulating cell membranes. However, the abnormal architecture in cancerous tissue may impede current differently and allow detection of differences between normal and abnormal or malignant prostate tissue.[@b9-cmr-3-109]

The aim of this research was to assess the utility of bioimpedance measurement as a rapid, cost-effective, and noninvasive adjunct to digital rectal examination and PSA in differentiating tumor from normal prostatic tissue.

One explanation as to why bioimpedance increases in cancer tissue is the distorted architecture of the gland, which prevents flow of current. Histologically, the prostate can be thought of as being composed of multiple layers of hollow glands (ie, tubes). Solid or gross tumor tissue is also composed of a histological array of tubes. The lumina in normal prostate tissue are open and have relatively large diameters, providing little resistance to flow. In contrast, as resistance increases, the current flow will decrease. Accordingly, in cancerous prostate tissue, the normal architecture of the lumina becomes distorted. The lumina of the tubes become much smaller, the walls of the glands become crowded, and the flow of current is impeded.[@b9-cmr-3-109]

The second explanation could be the electrochemical reaction in the anode related to the Chloride ions migration. The electrochemical reaction provides 4 H+ and is therefore an acid environment.

The pronounced elevations in prostatic tissue palmitoleic acid in cancer patients highlight a possible role of this fatty acid in neoplastic processes.[@b10-cmr-3-109]

We compared the results of PSA testing and biopsy with the results of EIS measurement to determine if the EIS system could be used as an adjunct to screening for prostate cancer.

Materials and methods
=====================

This study was approved by the regional ethic committee (Pesquisa CONEP, 125/10), and adhered to the ethical principles of the Declaration of Helsinki. Each patient signed an informed consent form, and confidentiality was maintained for all participants.

Subjects
--------

Patients attending consultations for signs and/or symptoms of a prostatic disorder and not receiving any prostate treatment, as well as responders to an advertisement were considered for enrolment into this study. Inclusion criteria were a high PSA test result (\>4 ng/mL) and/or a positive digital rectal examination with a clinical recommendation of prostate biopsy. Patients were excluded if they had previously undergone prostate-related chemotherapy or surgery, were currently receiving treatment for a prostatic disorder, had a neurological disorder precluding the ability to sign a consent form, if in the opinion of the investigator they were clinically unsuitable candidates for the trial, and/or had any contraindications to use of the EIS system. Use of the EIS system is contraindicated in the presence of an external defibrillator, skin lesions likely to come into contact with the electrodes, excessive perspiration, sinusitis (particularly frontal), cardiac pacemaker, electronic life support, any implanted electronic device, inability to remain still for three minutes, metallic pins or prostheses in digits or joints, pregnancy from the third trimester onwards, and absence of a limb.

Three hundred patients of mean age 65 (range 49--90) years were included in the study, and were examined in the office for signs and symptoms. A digital rectal examination was performed, and if indicated, the patients were sent to the laboratory for a PSA test. If the attending clinician subsequently decided that a patient should have a prostate biopsy, the patient underwent an EIS bioimpedance measurement prior to the biopsy.

Measurement of bioimpedance
---------------------------

The parameter used by the EIS is the delta of the electrical resistance values between the pathway value for left foot to right foot (anode to cathode) minus the pathway value for right foot to left foot (cathode to anode), expressed in numeric form on a scale from 0 to 100.

The EIS is a programmable electromedical system comprising a USB plug and hardware including an interface box, disposable electrodes, reusable plates, and reusable cables, with software installed on a computer. The system uses bioimpedance in bipolar mode with direct current, and measures the electrical conductivity of 11 pathways of the body, each recorded twice from anode to cathode and then from cathode to anode. The pathways are measured between four large tactile reusable electrodes (\>270 cm^2^) placed on the palms of the hands and soles of the feet, and smaller disposable electrodes (15 cm^2^) placed on the left and right forehead. Electrode polarization does not affect the bioimpedance measurement,[@b11-cmr-3-109] and the transmission of the current from the electrode to the hardware is performed by chronoamperometry.[@b12-cmr-3-109]

### EIS and electrical conductivity/chronoamperometry

With direct current, the plasma membrane acts as an insulator and the current is not able to penetrate the cell, so most of the current flows around the cell and therefore in the interstitial fluid.[@b13-cmr-3-109] Analysis of the direct current at the cathode and anode in electrolytic solution is performed at both the anode and the cathode.[@b13-cmr-3-109]

### Analysis at the cathode

The electrochemical reaction at the cathode is: $$2\text{H}_{2}\text{O} + 2\text{e} = \text{H}2\,(\text{gas}) + 2\,\text{OH} - (\text{base})$$

### Analysis at the anode

The electrochemical reaction for water at the anode is: $$2\text{H}_{2}\text{O} = \text{O}_{2}\,(\text{gas}) + 4\text{H}_{+} + 4\text{e} - (\text{acid})$$

Parameters analyzed
-------------------

Analysis of the specificity and sensitivity of the data was done in accordance with the biopsy results. Receiver-operating characteristic curves were constructed for the PSA value and tissue diagnosis and for the EIS data and tissue diagnosis, and algorithms were constructed for the PSA-EIS data and tissue diagnosis. Raw analysis of the EIS data as an adjunct to the PSA value was also undertaken.

Statistical analysis
--------------------

Statistical analysis of the results was performed using MedCalc software. The number of patients needed for the study was calculated to be 50 on the basis of α = 5%, at 80% power = F (Δ, N, variability DS), taking into account the judgment criteria Δ at approximately 50 DS (5% error).

A *P* value of \<0.005 was accepted as being statistically significant.

Results
=======

The results of this investigation showed that PSA had a sensitivity of 73.9% and a specificity of 51.9% for the detection of prostate cancer using a cutoff value \>4 ([Figure 1](#f1-cmr-3-109){ref-type="fig"}) and a sensitivity of 52.2% and specificity of 81.5% using a cutoff value ≥5.7 (*P* = 0.03) ([Figure 2](#f2-cmr-3-109){ref-type="fig"}).

The delta for the electrical conductivity (DE) of the pathway from left foot to right foot had a sensitivity of 62.5% and a specificity of 85.2% using a cutoff value ≤−5 (*P* = 0.0001) ([Figure 3](#f3-cmr-3-109){ref-type="fig"}).

The algorithms All (PSA Value multiplied by the delta value for the electrical conductivity) incorporating the delta of electrical conductivity and PSA value had a sensitivity of 91.5% and a specificity of 59.3% using a cutoff value ≤−10.52 (*P* = 0.0003) ([Figure 4](#f4-cmr-3-109){ref-type="fig"}).

Raw analysis of the EIS data as an adjunct to the PSA value ([Tables 1](#t1-cmr-3-109){ref-type="table"} and [2](#t2-cmr-3-109){ref-type="table"}).

Discussion
==========

Although strategies for primary prevention of prostate cancer are being tested, to date none are known to be effective. The most common strategy for reducing the burden of prostate cancer is screening, but this remains controversial. Urologists are often faced with the dilemma of elevated PSA in young patients. This is a difficult situation, because these patients often do not want to undergo a prostate biopsy and fear a diagnosis of prostate cancer due to the potential side effects of treatment, including the possibility of urinary incontinence and erectile dysfunction.

Criteria for a clinically useful screening test are: The disease must constitute a serious public health problemThe disease must be able to be diagnosed during an asymptomatic, localized phaseThe screening test must have an appropriate sensitivity, specificity, and predictive valueThe potential for cure must be greater in patients detected by screeningImproved outcomes related to screening must be shown and, after these criteria are satisfied, the cost-effectiveness of the screening program must also be justified.[@b14-cmr-3-109]

The importance of prostate cancer as a public health problem and the fact that it can be diagnosed during an asymptomatic, localized stage easily satisfy using PSA and digital rectal examination as screening tools for the first two of the above-listed criteria, but there are no clear answers for the rest.

An autopsy study in Detroit men found previously undiagnosed prostate cancer in 30% of men in the age range 20--40 years, and in more than one half of men older than 50 years. The prevalence of these unsuspected prostate cancers is consistently estimated to be about 33%.[@b15-cmr-3-109] These high rates of unsuspected prostate cancers are in sharp contrast with the 3.64% estimated lifetime risk of dying from prostate cancer, as well as the 1.8% detection rate of prostate carcinoma in pooled data from a recent meta-analysis. Once regional lymph node involvement is present, the probability of death from prostate cancer is 70%, and 50% of men with regional lymph node involvement will die in two years. Prostate cancer is a real risk for the aging man, because almost 10% of men older than 50 years are likely to develop clinically serious disease. Therefore, it should be detected at an early stage,[@b16-cmr-3-109] and to improve early detection rates it is necessary to increase the sensitivity of the screening tests used.

In the current study, the sensitivities of PSA and digital rectal examination screening were 72.1% and 53.2%, respectively. Reducing the PSA cutoff point from 4 ng/mL to 3 ng/mL can increase the sensitivity, but doing so will reduce further the positive predictive value.[@b16-cmr-3-109] It is also well known that PSA values for prostate cancer and benign prostate hyperplasia overlap considerably. Between 21% and 47% of men with histologically proven benign prostate hyperplasia have PSA levels \>4 ng/mL, and up to 43% of men with prostate cancer will have a PSA level \<4 ng/mL. This overlap makes it harder to differentiate benign prostate hyperplasia from prostate carcinoma in the absence of a biopsy. PSA values also increase with age.[@b17-cmr-3-109]

With prostate cancer, the risk of overdiagnosis is likely to be much more relevant than with other types of cancer screening, because in men aged 55--60 years, the risk of death from other causes is considerably higher than that from prostate cancer. It is estimated that for every patient who dies of prostate cancer, at least 380 others have prostate cancer that cannot be detected clinically.[@b18-cmr-3-109] The treatment of prostate cancer consists of radical surgery or radiotherapy, and both can cause complications, including a high frequency of sexual impotence, rectal and urinary dysfunction, as well and a mortality risk of 1%--2%.

The EIS technique, when used as a screening test, meets the requirements of the World Health Organization guidelines stating that a screening test should be acceptable to the population, be rapidly performed (no more than two minutes), cost-effective and noninvasive, and that the total cost of finding a case should be economically balanced in relation to medical expenditure as a whole.

In the present study, the positive predictive values for PSA and digital rectal examination were about 25% and 18%, respectively, which means one of four or five biopsies is unnecessary. Unnecessary biopsies can lead to multiple invasive procedures, anxiety for the patient, procedure-related complications, and a high cost of health care delivery. To reduce further unnecessary procedures, a meta-analysis[@b19-cmr-3-109] has proposed use of transrectal ultrasonography in patients with elevated PSA levels but benign digital rectal examination findings, followed by biopsy only of visible abnormal lesions. If findings on digital rectal examination are abnormal, the patient should undergo transrectal ultrasound and then a biopsy, regardless of the PSA value. A small, organ-confined prostate tumor has an estimated doubling time of about four years. Thus, it will take about 15 years for a 1 mL tumor to become life-threatening. It would be more straightforward to say that until there is evidence for effectiveness of screening in decreasing mortality, based on these growth rates, a man would need to have at least 15 years of remaining life expectancy to benefit from PSA screening.

In the US, there are 30.8 million men older than 50 years of age who qualify for PSA screening.[@b20-cmr-3-109] According to our calculations, based on fees charged at one urologist's office in New Jersey, the cost of PSA screening in all these men would be \$3.1 billion. Of this population, 10.1% (approximately 3.1 million men) will have PSA levels \>4 ng/mL. Assuming all patients with abnormal PSA levels are referred to a urologist for further evaluation, the first visit will cost \$275 (for the office visit, urine analysis, and culture). The second visit will involve sonography of the prostate, bladder, pelvis, and renal organs, as well as guided needle biopsy, which can cost \$2170 per patient. Therefore, the total cost of these two visits would exceed \$7.6 billion for 3.1 million men. Of 3.1 million biopsies performed, 75%, ie, 2.3 million will be negative for prostate carcinoma.

In our study, the EIS delta parameter had a good specificity of 85.2% and a sensitivity of 65.2%, although we noted that for the eight positive patients, none of which were identified by the delta parameter, four are undergoing diuretic treatment and one is receiving an alpha-blocker treatment.

Conclusion
==========

Using the EIS system as an independent predictor of prostate cancer, it has a good specificity of 85.2%. However, the sensitivity of 62.5% will be a problem. Using the PSA reference of ≥4.1 ng/mL, adjunctive use of the EIS system measuring bioimpedance and chronoamperometry could raise the sensitivity from 73.9% to 91.5% and the specificity from 51.9% to 59.3% in prostate cancer screening. To our knowledge, this is the first study using a noninvasive bioimpedance-chronoamperometry technique for prostate cancer screening. A longitudinal study is now under way to confirm our findings.

Thanks are extended to all the people who contributed to this investigation, Dr Daniel Ianni Filho for collecting the data for this study, Labclin Laboratorio de Análises Clínicas for PSA testing, CEAP Hospital for the biopsies, and LapMed for analysis of the biopsies.
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![Receiver-operating characteristic curve: PSA cutoff value \>4 ng/mL comparing positive biopsy group versus negative biopsy group.](cmr-3-109f1){#f1-cmr-3-109}

![Receiver-operating characteristic curve and data analysis: PSA cutoff value \>5.7 ng/mL comparing positive biopsy group versus negative biopsy group.](cmr-3-109f2){#f2-cmr-3-109}

![Receiver-operating characteristic curve and data analysis: Delta Electrical conductivity (DE) cutoff value ≤−5 comparing positive biopsy group versus negative biopsy group.\
\*Delta of the electrical conductivity between the pathway conductivity ieft foot- right foot minus the pathway conductivity right foot-left foot expressed in numeric values from 0--100.](cmr-3-109f3){#f3-cmr-3-109}

![Receiver-operating characteristic curve and data analysis: Test All cutoff value ≤−10.52 comparing positive biopsy group versus negative biopsy group.\
\*ALL Delta of the electrical conductivity value multiplied by the PSA value.](cmr-3-109f4){#f4-cmr-3-109}

###### 

Analysis of the positive patients group

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient code**   **Age**   **Positivie test = 1**\   **Delta DE**   **PSA**   **ALL \[DE-PSA\] \<−10.52**   **Delta DE ≤−0.5**   **PSA ≥−4**   **ALL \[DE -- PSA\] ≤ 10.52**   **Current treatment**
                               **Negative test = 0**                                                                                                                               
  ------------------ --------- ------------------------- -------------- --------- ----------------------------- -------------------- ------------- ------------------------------- -------------------------------------
  1ZH05              57        1                         −6             200.2     −1201.2                       X                    X             X                               No treatment

  1ZM13              90        1                         2              45        90                                                 X                                             Diuretics/furosemide

  1ZD19              67        1                         −9             26.0      −234                          X                    X             X                               ACE

  1ZL06              79        1                         −4             4.4       −17.6                                              X             X                               No treatment

  1Zd26              62        1                         −3             19        −57                                                X             X                               Diuretics/furosemide

  1ZS19              66        1                         −8             3.1       −24.8                         X                                  X                               No treatment

  1ZT15              64        1                         −8             11        −88                           X                    X             X                               No treatment

  1ZA31              69        1                         −6             3.0       −18.06                        X                                  X                               No treatment

  1ZL01              89        1                         −6             4.1       −24.6                         X                    X             X                               ACE, insulin NPH

  1ZB08              76        1                         −10            3.5       −35                           X                                  X                               ACE, diuretics

  1ZC30              56        1                         −8             3.5       −28                           X                                  X                               No treatment

  1ZA10              52        1                         −8             3.3       −26.4                         X                                  X                               Simvastatin, omeprazole

  1ZF06              84        1                         −2             7.5       −15                                                X             X                               ACE, ranitidine

  1ZS04              80        1                         −4             14        −56                                                X             X                               Diuretics, ACE

  1ZF03              57        1                         −8             2.3       −18.4                         X                                  X                               Angiotensin II antagonists, Crestor

  1ZS02              62        1                         −5             14.0      −70                           X                    X             X                               No treatment

  1Zx17              68        1                         −1             4.9       −4.9                                               X                                             ACE, diuretics

  1ZS28              76        1                         −6             319       −1914                         X                    X             X                               Metformin ACE, Diuretics

  1ZD22              74        1                         −10            6.5       −65                           X                    X             X                               ACE, simvastatin

  1ZR25              50        1                         −2             5.26      −10.52                                             X             X                               No treatment

  1ZF28              71        1                         −5             6.0       −30                           X                    X             X                               No treatment

  1ZM11              59        1                         −2             9         −18                                                X             X                               Alpha blockers

  1WR28              55        1                         −5             4.2       −21                           X                    X             X                               ACE, selozok
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** X = Right results in reference to the biopsies.

###### 

Analysis of the negative patients group

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient code**   **Age**   **Positive test = 1**\   **Delta DE**   **PSA**   **All (DE-PSA) ≤−10.52**   **Delta DE ≤−5**   **PSA \>4**   **All (DE-PSA) ≤−10.52**   **Correct treatment**
                               **Negative test = 0**                                                                                                                    
  ------------------ --------- ------------------------ -------------- --------- -------------------------- ------------------ ------------- -------------------------- ----------------------------------------------------
  1ZE22              55        0                        −3             3.2       −9.6                       X                  X             X                          No treatment

  1ZC01              57        0                        1              3.3       3.3                        X                  X             X                          Insulin, corticosteroid, ACE, Diuretics, metformin

  1ZL10              73        0                        −4             16        −64                        X                                                           No treatment

  1ZB11              65        0                        0              2.6       0                          X                  X             X                          No treatment

  1Zd08              64        0                        6              4.9       29.4                       X                                X                          No treatment

  1ZD11              60        0                        −6             4.4       −26.4                                                                                  ACE, imipcamin, ranitidine

  1Zd30              64        0                        −4             4.7       −18.8                      X                                                           No treatment

  1ZC20              68        0                        3              5.52      16.56                      X                                X                          ACE

  1ZP09              81        0                        −6             5.61      −33.66                                                                                 Angiotensin II inhibitor, Simvastatin

  1ZL20              76        0                        5              2.8       14                         X                  X             X                          ACE

  1ZA04              62        0                        −2             3.1       −6.2                       X                  X             X                          No treatment

  1Zd18              63        0                        −2             2.7       −5.4                       X                  X             X                          No treatment

  1ZG21              67        0                        0              3.2       0                          X                  X             X                          Simvastatin, bromazepan

  1ZB01              71        0                        −4             4.7       −18.8                      X                                                           Chondroitin

  1ZA26              77        0                        −5             7.0       −35                        X                                X                          Cefalexin

  1ZF11              69        0                        −4             3.0       −12                        X                  X             X                          Digoxin, ACE

  1ZA09              53        0                        −10            4.2       −42                                                                                    No treatment

  1ZD11              54        0                        −1             3.3       −3.3                       X                  X             X                          no treatment

  IZdI8              68        0                        −4             7.1       −28.4                      X                                                           No treatment

  1ZL11              73        0                        −4             4         −16                        X                  X                                        ACE

  1ZC11              69        0                        3              5.7       17.1                       X                                X                          No treatment

  1ZG13              62        0                        −2             3.1       −6.2                       X                  X             X                          No treatment

  1ZI28              61        0                        −2             2.9       −5.8                       X                  X             X                          Omeprazol

  1ZD10              69        0                        −4             23        −92                        X                                                           ACE

  1ZL14              62        0                        2              10        20                         X                                X                          Angiotensin II inhibitor, Ranitidine

  1ZM03              53        0                        −3             2.8       −8.4                       X                  X             X                          Angiotensin II inhibitor

  1ZA31              49        0                        −2             3.5       −7                         X                  X             X                          Simvastatin, omeprazole
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** X = Right results in reference to the biopsies.
